Trial · NCT00806026
Results by group159
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 159
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Restless Legs Syndrome (RLS) Symptom Severity | Pregabalin 300 mg | 22.30 | Standard Deviation 5.73 | Units on a Scale | |
| Restless Legs Syndrome (RLS) Symptom Severity | Pramipexole 0.25 mg | 22.40 | Standard Deviation 5.37 | Units on a Scale | |
| Restless Legs Syndrome (RLS) Symptom Severity | Pramipexole 0.5 mg | 22.10 | Standard Deviation 5.19 | Units on a Scale | |
| Restless Legs Syndrome (RLS) Symptom Severity | Placebo | 22.40 | Standard Deviation 5.58 | Units on a Scale | |
| Change From Baseline in the RLS Symptom Severity at Week 12 | Pregabalin 300 mg | -11.80 | Standard Error 0.47 | Units on a Scale | |
| Change From Baseline in the RLS Symptom Severity at Week 12 | Pramipexole 0.25 mg | -7.90 | Standard Error 0.49 | Units on a Scale | |
| Change From Baseline in the RLS Symptom Severity at Week 12 | Pramipexole 0.5 mg | -10.50 | Standard Error 0.47 | Units on a Scale | |
| Change From Baseline in the RLS Symptom Severity at Week 12 | Placebo | -7.30 | Standard Error 0.48 | Units on a Scale | |
| Percentage of Participants Responding to Treatment at Week 12 | Pregabalin 300 mg | 71.40 | Percentage of participants | ||
| Percentage of Participants Responding to Treatment at Week 12 | Pramipexole 0.25 mg | 51.20 | Percentage of participants | ||
| Percentage of Participants Responding to Treatment at Week 12 | Pramipexole 0.5 mg | 62.70 | Percentage of participants | ||
| Percentage of Participants Responding to Treatment at Week 12 | Placebo | 46.80 | Percentage of participants | ||
| Percentage of Participants With Augmentation | Pregabalin 300 mg | 1.70 | Percentage of participants | ||
| Percentage of Participants With Augmentation | Pramipexole 0.25 mg | 6.60 | Percentage of participants | ||
| Percentage of Participants With Augmentation | Pramipexole 0.5 mg | 9.00 | Percentage of participants | ||
| Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO) | Pregabalin 300 mg | 90.60 | Standard Deviation 76.10 | minutes | |
| Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO) | Pramipexole 0.25 mg | 100.20 | Standard Deviation 85.92 | minutes | |
| Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO) | Pramipexole 0.5 mg | 83.90 | Standard Deviation 77.35 | minutes | |
| Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO) | Placebo | 79.50 | Standard Deviation 69.85 | minutes | |
| Change From Baseline in SSQ: Subjective WASO at Week 12 | Pregabalin 300 mg | -49.86 | Standard Error 3.06 | minutes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00806026/results